Venezuela - español - Instituto Nacional de Higiene

medifarm inversiones y representaciones, c.a. - albumina humana - solucion - 20 %

Unión Europea - español - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxística - inmunosupresores - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

medochemie iberia s.a. - cefuroxima - polvo para soluciÓn inyectable y para perfusiÓn - 1.500 mg - cefuroxima 1500 mg - cefuroxima

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

medochemie iberia s.a. - cefuroxima - polvo para soluciÓn inyectable y para perfusiÓn - 750 mg - cefuroxima 750 mg - cefuroxima

Unión Europea - español - EMA (European Medicines Agency)

takeda pharmaceuticals international ag - icatibant - angioedemas, hereditario - terapia cardiaca - firazyr está indicado para el tratamiento sintomático de los ataques agudos de angioedema hereditario (aeh) en adultos (con deficiencia de inhibidor de la c1-esterasa).

Unión Europea - español - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - agentes antineoplásicos - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. sólo existen datos limitados sobre la eficacia y la seguridad de los pacientes tratados previamente con anticuerpos monoclonales incluyendo rituximab o en pacientes refractarios a la anterior rituximab y quimioterapia. consulte la sección 5. 1 para más información. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab ha demostrado reducir la tasa de progresión del daño articular medido por rayos x y para mejorar la función física, cuando se administra en combinación con metotrexato. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

Unión Europea - español - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - lanadelumab - angioedemas, hereditario - other hematological agents - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in patients aged 2 years and older.

Unión Europea - español - EMA (European Medicines Agency)

biocryst ireland limited - berotralstat dihydrochloride - angioedemas, hereditario - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, hereditario - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Chile - español - ISPC (Instituto de Salud Pública de Chile)

betco chile spa - cloruro de dideci/dimetilamonio 32% cloruro de bencii-c1.2-1.6-alquildimeti/48% - cloruro de dideci/dimetilamonio 32% cloruro de bencil-c12-16-alquildimetil 48 % 5,29 g